179 results on '"Cossmann, Anne"'
Search Results
2. Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion
3. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency
4. Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
5. Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine
6. Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage
7. Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
8. Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination
9. SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study
10. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
11. Versorgung von rheumatologischen Patienten während des Lockdowns im Frühjahr 2020: Telemedizin, Delegation, Patientenzufriedenheit und Impfverhalten
12. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
13. Reverse mutational scanning of spike BA.2.86 identifies the epitopes contributing to immune escape from polyclonal sera
14. Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany
15. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
16. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
17. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
18. Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals
19. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination
20. Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3
21. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals
22. Migrant healthcare workers during COVID-19: bringing an intersectional health system-related approach into pandemic protection. A German case study
23. Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals
24. Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
25. Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
26. The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
27. The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
28. Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
29. Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
30. Long-term Consequences of COVID-19 and the Pandemic: Protocol for a Web-Based, Longitudinal Observational Study (DEFEAT)
31. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients
32. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
33. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
34. Versorgung von rheumatologischen Patienten während des Lockdowns im Frühjahr 2020
35. The Impact of COVID-19 Vaccination on the Social Participation of Immunocompromised Persons – Results of a Multicenter Observational Study
36. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
37. Healthcare Workers' Perceptions and Medically Approved COVID-19 Infection Risk: Understanding the Mental Health Dimension of the Pandemic. A German Hospital Case Study
38. SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
39. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern
40. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
41. Additional file 1 of SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study
42. Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
43. BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
44. BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
45. The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic
46. Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
47. Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2
48. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy
49. Telemedizin und Delegation während des COVID-19-Lockdowns im Frühjahr 2020
50. SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.